Snapshot of the Pharma and Biotech world: Q3 Updates and Industry Insights

Pharma and BioTech Daily

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Moderna exceeded expectations for COVID-19 vaccine sales in the third quarter, but sales of their respiratory syncytial virus vaccine fell short. Gilead also beat expectations in Q3 due to strong sales of their HIV drug. Sarepta has halted development of a next-gen DMD drug, vesleteplirsen, and reported strong sales of elevidys. Lilly cited wholesalers as the reason for slow sales of their GLP-1 products, while Novo reported no supply issues with their rival medicines. The gene therapy sector is highlighted in an on-demand webinar. Teva reported strong demand for generics in Q3 and expects higher revenue in 2024. Viracta Therapeutics has cut staff as part of resource reprioritization. Cell therapy biotechs are seeking expertise in autoimmune diseases. Thank you for listening to Pharma and Biotech daily.